Danaher Corp
DHRQ1 2023(DHR Q4 FY2022)Estimated1% AI
AI Revenue %
1%
AI Fair Value
$661.0M
AI Revenue (Q)
$76.6M
Total Revenue (Q)
$7.7B
Source: SEC EDGAR 10-K Filing
View 10-K on SEC.govAnalysis
Q4 FY2022 (derived from full-year 10-K ended December 31, 2022). Full-year sales $31,471M; nine-month sales $23,102M; therefore Q4 sales = $8,369M. In Q4 2022, DHR realigned segments: Biotechnology $8,758M (FY), Life Sciences $7,036M (FY), Diagnostics $10,849M (FY), Environmental & Applied Solutions $4,828M (FY). No AI revenue is disclosed anywhere in the 10-K. The only mention of AI is absent from this filing. Products include bioprocessing (Cytiva), instruments (Beckman, Leica, SCIEX), and diagnostics (Cepheid, Radiometer). Conservative 1% for embedded algorithms. Math: ~$84M estimated / $8,369M total = ~1.0%.
Analyzed by claude-opus-4-6
Quoted Figures
Total Sales $31,471 [year ended December 31, 2022]
10-K FY2022, Note 6 Segment Information
Biotechnology $8,758; Life Sciences $7,036; Diagnostics $10,849; Environmental & Applied Solutions $4,828 [full year 2022]
10-K FY2022, Note 6 Segment Information
AI Products Identified (Ring 1)
Embedded instrument algorithms (digital pathology, flow cytometry, clinical chemistry)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Biotechnology consumables/bioprocessingLife Sciences instrumentsDiagnostics instrumentsEnvironmental & Applied Solutions
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix